This efficacy was not observed with commercially available untargeted formulations, such as OnivydeTM, nor with untargeted high-payload lipid nanoparticles (HPLN/irinotecan) at the same dose, highlighting the critical contribution of CD99-mediated tumor targeting (19). The gene discussed is CD99; the disease is neoplasm.